Drospirenone

• UNSPSC Description:

  Drospirenone (Dihydrospirorenone) is an orally active fourth-generation progestin that interacts with the progesterone receptor (PR) and androgen receptor (AR). Drospirenone significantly decreases both plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA) via the AR. Drospirenone can produce DNA damage in bone marrow cells of female mice. [1][2][3][4].

• Target Antigen:

  Androgen Receptor; Progesterone Receptor

• Type:

  Reference compound

• Related Pathways:

  Vitamin D Related/Nuclear Receptor

• Field of Research:

  Cancer; Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/drospirenone.html

• Purity:

  98.45

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  C[C@@]12[C@](OC3=O)(CC3)[C@@H](C4)[C@@H]4[C@@]1([H])[C@@]([C@@H]5[C@H]6C5)([H])[C@]([C@](C6=CC7=O)(CC7)C)([H])CC2

• Molecular Weight:

  366.49

• References & Citations:

  [1]Fuhrmann, U., et al., The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception, 1996. 54(4): p. 243-51.|[2]Muhn, P., et al., Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception, 1995. 51(2): p. 99-110.|[3]Warming, L., et al., Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis. Climacteric, 2004. 7(1): p. 103-11.|[4]Marqueño A, et al. Drospirenone induces the accumulation of triacylglycerides in the fish hepatoma cell line, PLHC-1 [J]. Science of The Total Environment, 2019, 692: 653-659.|[5]Sabouni R, et al. Drospirenone effects on the plasminogen activator system in immortalized human endometrial endothelial cells [J]. Reproductive sciences, 2021, 28: 1974-1980.|[6]Mir A H, et al. Genotoxic effects of drospirenone and ethinylestradiol in human breast cells (in vitro) and bone marrow cells of female mice (in vivo) [J]. Drug and Chemical Toxicology, 2022, 45(4): 1493-1499.|[7]Motivala A, et al. Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens? [J]. Drugs, 2007, 67: 647-655.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  67392-87-4